Originaalravimid

Originaalravimid, also known as pioneer drugs or reference products, are the first version of a medication that contains a newly developed active pharmaceutical ingredient. These drugs are typically developed by pharmaceutical companies through extensive research and development, often involving significant investment in clinical trials to demonstrate their safety and efficacy. Once a new active ingredient is discovered and proven effective, the originating company obtains a patent, which grants them exclusive marketing rights for a specific period. This patent protection allows the company to recoup their research and development costs and profit from their innovation.

During the patent period, only the originating company can legally manufacture and sell the original drug. After the patent expires, other pharmaceutical companies are permitted to produce and market generic versions of the drug. Generic drugs contain the same active ingredient as the original medication and are required to meet the same standards of quality, safety, and efficacy as established by regulatory authorities. They are generally sold at a lower cost compared to the original drug because generic manufacturers do not incur the initial research and development expenses. The availability of generic alternatives is a crucial aspect of healthcare affordability, making essential treatments more accessible to a wider population. The term "originaalravimid" emphasizes their status as the first approved form of a particular therapeutic compound.